News Room

Latest Media Releases for Huntington\'s Disease

Huntington's Disease

Prana’s PBT2 presented at the Huntington’s Disease Society of America National Convention: Prana’s ‘Reach2HD’ Phase II trial on track

Prana Biotechnology today announced that an update on Prana’s Phase 2 clinical trial in Huntington disease (HD) was presented at the HDSA annual National Convention held in Las Vegas, Nevada over the weekend. Professor Ira Shoulson, Professor of Neurology, Pharmacology and Human Science and Director, Program for Regulatory Science & Medicine at Georgetown University spoke to the ‘Reach2HD’ trial objectives and potential future of PBT2 as a novel therapeutic strategy for the treatment of HD.

1 2